Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

856
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
856
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.4K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Notable clinical activity of immune checkpoint inhibitors with or without brentuximab vedotin in relapsed or refractory gray zone lymphoma.

Haematologica·2026
Same author

Practical recommendations for infectious prophylaxis and vaccination in multiple myeloma patients.

Frontiers in medicine·2026
Same author

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Clock gene signature predicts insomnia and links to sleep/circadian parameters.

Translational psychiatry·2026
Same author

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England)·2026
Same author

Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).

British journal of haematology·2026

Related Experiment Video

Updated: Apr 18, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Long-term survival in multiple myeloma.

Cristina João1, Carlos Costa2, Inês Coelho2

  • 1Department of Hematology, IPOFG Lisboa, Portugal ; Clinical Research Unit, IPOFG Lisboa, Portugal.

Clinical Case Reports
|January 24, 2015
PubMed
Summary

Long-term survival in multiple myeloma is improving, but many patients still face challenges. This study examines four long-term survivors, revealing diverse clinical paths and treatment needs for extended survival in multiple myeloma.

Keywords:
Clinical characteristics in multiple myelomacytogeneticsmultiple myeloma long survivorstoxicities

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Related Experiment Videos

Last Updated: Apr 18, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Multiple myeloma patient survival has significantly improved in the last decade.
  • Despite advances, median overall survival remains under five years.
  • A small subset of patients achieve long-term survival exceeding ten years.

Observation:

  • This paper details four multiple myeloma cases with non-homogeneous clinical presentations and disease evolution.
  • These long-term survivors exhibit varied responses to treatment.
  • Some long-term survivors require frequent interventions, including autologous stem cell transplantation and novel drug therapies.

Findings:

  • Long-term survival in multiple myeloma is not solely dependent on achieving deep responses.
  • Treatment intensity and frequency vary considerably among long-term survivors.
  • The clinical course and treatment strategies for long-term multiple myeloma survivors are highly individualized.

Implications:

  • Understanding the diverse clinical trajectories of long-term multiple myeloma survivors is crucial.
  • Further research into the factors contributing to extended survival may inform treatment strategies.
  • Investigating the relationship between treatment patterns and long survivorship can optimize care for multiple myeloma patients.